BTA test

BTA test

Bladder tumour antigen test. A qualitative, point-of-care test that identifies a human complement factor H-related protein, which is produced by several human bladder cell lines but not by non-malignant epithelial cell lines. It has a claimed sensitivity comparable to that of cytology for high-grade tumours and claimed to be better than cytology for low-grade tumours.
References in periodicals archive ?
17] To understand the nuances of the BTA test and the urine cytology test in diagnosis, we conducted a systematic review of published findings and used meta-analysis techniques to quantitatively combine results.
A significant interaction was observed between exercise and medication use based on results of the BTA test and the Digit Span Forward and Backward Task.
Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
Because original BTA test sensitivity (approximately 40%) was no better than that of cytology, several assay modifications were introduced, including the BTA stat and BTA TRAK.
He has also served as President and CEO of Bard Diagnostics (formerly Bainbridge Sciences), a pioneering cancer diagnostics company that developed and launched the BTA test, the first diagnostic test for bladder cancer approved by the U.
3,4] A number of novel immunoassays for cancer-associated proteins in voided urine have been investigated as diagnostic tool to replace cytology, including BTA test, BTA Stat test, NMP22 and Immunocyt.
The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladder.
The new, rapid BTA stat test is even simpler to perform and improves upon the original Bard BTA Test.
The Bard BTA Test takes three minutes to perform and, at about $17 per test for the laboratory, it is approximately one third of the cost of voided urine cytology, the conventional noninvasive test for bladder cancer.
The clinical trial, conducted in Germany, France and England, compared the BTA Test to voided urine cytology and bladder wash cytology in patients suspected of having bladder cancer.
The Bard BTA test is used for the qualitative measurement of bladder tumor associated analytes in human urine to aid in the management of bladder cancer patients.